Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
13 11월 2023 - 11:00PM
Business Wire
-- Phase 2 Study in SLE (Synergy) Ongoing
--
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading
clinical-stage immunotherapy company focused on developing
innovative treatments for autoimmune and inflammatory diseases,
announced today that the Company presented new translational data
for acazicolcept (ALPN-101) in systemic lupus erythematosus (SLE)
at the American College of Rheumatology Convergence 2023, November
10-15, 2023.
Acazicolcept Presentation Highlights Include:
- Acazicolcept target-related genes (ICOS, CD80, CD86) are
upregulated in the T and B cells of SLE patients compared to
healthy adults.
- Acazicolcept suppresses expression of genes associated with T
cell activation and/or implicated in the pathogenesis of SLE more
potently than inhibitors of the CD28 or ICOS pathways.
- Acazicolcept reduces pathogenic hypergammaglobulinemia and
glomerular IgG deposition in a mouse model of lupus.
“These data reinforce the importance of multiple key pathways in
the pathogenesis of SLE and further support the potential for
acazicolcept, a first-in-class molecule, in its treatment,” said
Stanford Peng, M.D., Ph.D., President and Head of Research and
Development at Alpine. “Because CD28 and ICOS are closely related
receptors that can both mediate T cell costimulation, inhibition of
both may be required to provide optional outcomes in multiple
autoimmune diseases. Clinical investigation of acazicolcept for the
treatment of SLE, such as in our ongoing phase 2 study, Synergy,
continues to be supported.”
American College of Rheumatology
Convergence 2023
Date/Time: Sunday, November 12, 2023, 9:00 am – 11:00 am
PT Poster Title: Dual Blockade of ICOS and CD28 with
Acazicolcept (ALPN-101) Reveals Non-Redundant Roles of T Cell
Co-Stimulation Pathways in Systemic Lupus Erythematosus Abstract
ID: 1553700 Session Name: SLE – Treatment Poster I
Location: Exhibit Hall, San Diego Convention Center, San
Diego, CA Presenter: Elizabeth Repash, M.S., Alpine Immune
Sciences Link to Poster: https://bit.ly/3QPjR5D
About Acazicolcept (ALPN-101)
Acazicolcept (ALPN-101) is a first-in-class, dual inhibitor of
the CD28 and ICOS T-cell costimulatory pathways being developed for
treatment of systemic lupus erythematosus (SLE). By simultaneously
blocking two key costimulatory pathways, acazicolcept has the
potential to improve outcomes in patients suffering from severe
autoimmune/inflammatory diseases. Preclinical studies have
demonstrated efficacy in models of SLE, Sj�gren’s syndrome,
arthritis, inflammatory bowel disease, multiple sclerosis, type 1
diabetes, uveitis, and graft versus host disease.
About Alpine Immune
Sciences
Alpine Immune Sciences is committed to leading a new wave of
immune therapeutics. With world-class research and development
capabilities, a highly productive scientific platform, and a proven
management team, Alpine is seeking to create first- or
best-in-class multifunctional immunotherapies via unique protein
engineering technologies to improve patients’ lives. Alpine has
entered into strategic collaborations with leading global
biopharmaceutical companies and has a diverse pipeline of clinical
and preclinical candidates in development. For more information,
visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on X
and LinkedIn.
Forward-Looking
Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
not based on historical fact and include statements regarding our
platform technology and potential therapies; the timing of and
results from clinical trials and preclinical development
activities; clinical and regulatory objectives and the timing
thereof; expectations regarding the sufficiency of cash, cash
equivalents, restricted cash, and investments to fund our planned
operations through 2025; the potential efficacy, safety profile,
future development plans, addressable market, regulatory success,
and commercial potential of our product candidates; our ability to
achieve additional milestones in our collaborations and proprietary
programs; the progress and potential of our ongoing development
programs; the timing of our public presentations and potential
publication of future clinical data; the efficacy of our clinical
trial designs; anticipated enrollment in our clinical trials and
the timing thereof; expectations regarding our ongoing
collaborations; and our ability to successfully develop and achieve
milestones in our development programs. Forward-looking statements
generally include statements that are predictive in nature and
depend upon or refer to future events or conditions and include
words such as “may,” “will,” “should,” “would,” “expect,” “plan,”
“intend,” and other similar expressions, among others. These
forward-looking statements are based on current assumptions that
involve risks, uncertainties, and other factors that may cause
actual results, events, or developments to be materially different
from those expressed or implied by such forward-looking statements.
These risks and uncertainties, many of which are beyond our
control, include, but are not limited to: clinical trials may not
demonstrate safety and efficacy of any of our product candidates;
our ongoing discovery and preclinical efforts may not yield
additional product candidates; our discovery-stage and preclinical
programs may not advance into the clinic or result in approved
products; any of our product candidates may fail in development,
may not receive required regulatory approvals, or may be delayed to
a point where they are not commercially viable; we may not achieve
additional milestones in our proprietary or partnered programs; the
impact of competition; adverse conditions in the general domestic
and global economic markets; the impact of pandemics, or other
related health crises on our business, research and clinical
development plans and timelines and results of operations,
including the impact on our clinical trial sites, collaborators,
and contractors who act for or on our behalf; as well as the other
risks identified in our filings with the Securities and Exchange
Commission. These forward-looking statements speak only as of the
date hereof and we undertake no obligation to update
forward-looking statements, and readers are cautioned not to place
undue reliance on such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231113001781/en/
Media and Investor Relations
Contact: Temre Johnson Alpine Immune Sciences, Inc.
ir@alpineimmunesciences.com media@alpineimmunesciences.com
Alpine Immune Sciences (NASDAQ:ALPN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Alpine Immune Sciences (NASDAQ:ALPN)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024